Positioning your TechBio product in developmental and stem cell science

Reading time: 8 minutes

The Pillar 2 series on why ancillary technologies for stem cell science fail closed on an observation that deserves its own pillar. A product can survive every failure mode that series described — it can be reproducible, scale, sit comfortably on the right side of the regulatory cliff, integrate with the rest of the toolchain, and still fail commercially — because no one has decided, clearly and early, who it is for, what it displaces, and why a buyer should change a working process to adopt it. That decision is positioning. It is the subject of this pillar, and it is where much of the advisory work at StemCells.Help begins.

Positioning is not branding. It is not a tagline, a colour palette, or a conference booth. It is the working hypothesis about where your product fits in a field you may not have trained in, who will buy it, and which of their current frustrations it credibly solves. Every choice downstream — material specifications, validation plan, pricing, regulatory route, sales motion — follows from that hypothesis. Get it wrong and the company will feel the consequences as stalled sales cycles, pilots that never convert, and revenue that is always one quarter away.

Why TechBio positioning is unusually difficult

Ancillary technologies for developmental and stem cell biology sit at an awkward intersection. The science they enable is still developing. The markets they serve — biomedical discovery, cell and gene therapy manufacturing, animal breeding, species preservation, food production, human rejuvenation — are at different stages of maturity, with different buyers, different regulatory expectations, and different tolerances for novelty. A tool developed against one of these markets may have obvious relevance in another that the founding team has never worked in and cannot readily assess.

This difficulty is compounded by two structural features of the sector. First, the decision makers at TechBio companies are typically engineers, physicists, data scientists, or business builders who have an educated professional awareness of developmental and stem cell biology but not the kind of operational familiarity that lets them read between the lines of a published protocol. They know the field matters. They may not know which specific bottlenecks their technology is best placed to relieve, or which users experience those bottlenecks most acutely. Second, their buyers are scientists and engineers whose trust is earned through peers and reputation rather than through marketing. A positioning story that sounds like marketing to those buyers is worse than no story at all.

The practical consequence is that positioning in this field cannot be imported from generic B2B playbooks. It has to be built from the biology outward: from the state of the art in the target application, through the specific workflow steps where the technology can credibly help, to the people who will evaluate it and the language they respect.

What positioning actually requires

The StemCells.Help approach to positioning treats it as a sequence of five connected questions. None can be answered in isolation. Each article in this pillar takes one of them as its subject.

Which workflows does your product actually serve? Before you can talk about buyers, you need a defensible view of which steps in which workflows your technology addresses, and what the current state of the art is at each of those steps. This is the domain of the Ideal Target Profile: the specific scientific and technical problem your product is best suited to solve, and the life sciences market segments where that problem is most acute. Get this wrong and every subsequent decision compounds the error.

Who else operates in the space, and how does your product differ on substance? In categories that barely exist yet, the competitive landscape is often misread. Companies describe themselves as the only player addressing their chosen problem, which is usually a sign that the problem has been framed too narrowly to be commercially meaningful. Mapping competitive landscape in an emerging category requires looking beyond direct competitors to adjacent technologies, incumbent workarounds, and the tools that buyers would use if yours did not exist.

Do the users you think need your tool actually need it? This is demand validation, and it is harder in TechBio than in software because biology takes time. But the principle is the same: the cheapest way to test a positioning hypothesis is to ask the people it is meant to describe, before committing to the development path that depends on it. Demand validation in this field draws on workflow shadowing, problem-first interviews, and pilot evaluations with agreed success criteria.

Who is the buyer, and what training do they bring to the decision? The Ideal Client Profile for an ancillary technology in stem cell science is rarely a developmental biologist. It is more often a founder, CTO, or scientific officer trained in a different discipline, making procurement decisions on behalf of a team with mixed expertise. Defining the buyer in these circumstances means understanding how they read evidence, which signals they trust, and how the internal decision moves from technical evaluation to purchase order.

Can you describe what your product does in language that earns trust? The language of the academic paper — mechanism of action, statistical significance, comparison with prior art — is not the language of the procurement decision. Nor is the language of generic B2B marketing, which in this field triggers immediate scepticism. Framing technical value in this pillar examines how to describe a product in terms that biologists and engineers recognise as honest, specific, and grounded in the work they do.

Across all five questions sits a sixth that applies most acutely to emerging applications where developmental and stem cell biology is itself the enabling technology: what prior art in laboratory and domesticated species already exists that your product can learn from, and what established knowledge from mouse, sheep, cattle, pig, and human systems can shorten your path. This is where positioning connects to development, because a product that ignores forty years of prior art is not just commercially naive; it is scientifically incomplete.

Positioning is a product decision, not a marketing output

The argument of this pillar is straightforward. Positioning is not what you do once the product is built. It is how you decide what to build. A team that defers positioning until the product is ready for launch will find that the product has been built for assumptions that never survived contact with the market, and that correcting course requires rework that the company cannot afford.

This is particularly true for ancillary technologies serving developmental and stem cell science because the feedback loops are slow. You cannot A/B test a cell culture medium in a week. A pilot evaluation at a manufacturing site takes months. A clinical customer's qualification of a new input can take a year or more. Every positioning error compounds through development timelines that are measured in years, and the companies that survive are the ones that make the fewest errors early, not the ones that correct the most errors late.

The StemCells.Help positioning framework was built through forty years at the interface between developmental biology, stem cell manufacturing, and technology commercialisation, including the foundation and scientific leadership of Roslin Cells from 2005 through 2019 and its role in establishing Scotland's advanced cell therapy manufacturing capability. It is not a theoretical scheme. It is the set of questions that, asked early and answered honestly, have repeatedly determined whether a TechBio product found its market or drifted past it.

What this series covers

Each of the articles below takes one of the positioning questions introduced above and examines it in practical terms — what the work looks like, where it most commonly goes wrong, and what a TechBio founder or executive can do to ground their decisions in evidence rather than assumption.

How to identify which stem cell workflows your product actually serves. Mapping the specific steps in specific workflows where your technology can credibly help, and distinguishing those from the steps where it merely could be applied.

Mapping competitive landscape when your category barely exists yet. How to see adjacent technologies, incumbent workarounds, and the real field of alternatives buyers consider, when direct competitors are few or absent.

Demand validation: testing whether the scientists you think need your tool actually do. Workflow shadowing, problem-first interviews, and pilot evaluation designs that generate evidence before you commit to a development path.

Defining your buyer when the decision maker trained in a different discipline. How buyers with engineering, physics, or business backgrounds read evidence, and how to reach them without either condescending or losing them in unexplained biology.

Framing technical value in language that resonates with biologists and engineers. Writing about a product in terms that technical buyers respect: specific, grounded, honest about what the evidence does and does not show.

What prior art in laboratory and domesticated species can teach product developers. How established knowledge from mouse, sheep, cattle, pig, and human systems can inform product design and shorten the path for applications where the biology is the enabling technology.

The audience for this pillar is the same as for Pillar 2: founders, CTOs, and scientific officers of ancillary TechBio companies building for developmental and stem cell science. The biology assumes the baseline provided by the Pillar 1 series. The commercial analysis assumes working familiarity with product development and startup operations. Pillars 4 and 5, on species preservation and human ageing and rejuvenation respectively, extend the positioning logic to applications where developmental and stem cell biology is itself the ancillary technology that others depend on.

About StemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID: 0000-0003-0745-2504

Web: stemcells.help